Roman R,1 Colomer A,1 Erill N,1 Verdú M,2 Ibáñez R,1 Cordon-Cardo C,1 Puig X.1,2
1BIOPAT. Biopatologia Molecular, Grup Assistència & 2HISTOPAT Laboratoris, Barcelona, Catalonia, Spain.
Background: Irinotecan (CPT-11) is currently used as first- or second-line treatment for colorectal cancer, either alone or in combination with 5-fluorouracil based regimens. UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzes the inactivation of SN-38, the active metabolite of irinotecan, through glucuronidation. UGT1A1*28, a polymorphic variant of this enzyme displaying an additional TA dinucleotide in the promoter TATA box, has been […]